Recs Provided for Transcatheter Aortic Valve Replacement

Share this content:
Recs Provided for Transcatheter Aortic Valve Replacement
Recs Provided for Transcatheter Aortic Valve Replacement

FRIDAY, Jan. 6, 2017 (HealthDay News) -- In a clinical expert consensus report published online Jan. 4 in the Journal of the American College of Cardiology, a series of practice point-of-care checklists help provide guidance on the use of transcatheter aortic valve replacement (TAVR).

Noting that TAVR is a new technology for patients with severe aortic valvular stenosis, and is currently approved for high surgical risk or inoperable patients, Catherine M. Otto, M.D., from the University of Washington in Seattle, and colleagues offer guidance on its use.

The authors present point-of-care checklists and algorithms. These are provided in four specific areas: (1) preprocedure evaluation of patients being considered for TAVR, including selection criteria, discussion of shared decision making, and consideration of other risk assessments; (2) imaging modalities and measurements, including which modalities are required and when; (3) key issues in TAVR performance and management of complications; and (4) recommendations for patient follow-up, including immediate post-procedure care and longer-term follow-up to ensure continuity of care.

"TAVR is one of the most rapidly expanding technologies in medical care today, and as our population ages, we will see increasing numbers of people with severe aortic valve stenosis, so it is important to provide guidance on optimal use of this treatment," Otto said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »